NL970044I1 - Benzimidazoolderivaten, de bereiding en toepassingdaarvan. - Google Patents

Benzimidazoolderivaten, de bereiding en toepassingdaarvan.

Info

Publication number
NL970044I1
NL970044I1 NL970044C NL970044C NL970044I1 NL 970044 I1 NL970044 I1 NL 970044I1 NL 970044 C NL970044 C NL 970044C NL 970044 C NL970044 C NL 970044C NL 970044 I1 NL970044 I1 NL 970044I1
Authority
NL
Netherlands
Prior art keywords
anion
benzimidazole
substd
opt
preparation
Prior art date
Application number
NL970044C
Other languages
English (en)
Other versions
NL970044I2 (nl
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27526589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL970044(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NL970044I1 publication Critical patent/NL970044I1/nl
Publication of NL970044I2 publication Critical patent/NL970044I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
NL970044C 1990-04-27 1997-12-19 Benzimidazoolderivaten, de bereiding en toepassingdaarvan. NL970044I2 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP11314890 1990-04-27
JP14194290 1990-05-30
JP20866290 1990-08-06
JP26457990 1990-10-01
JP41367990 1990-12-24

Publications (2)

Publication Number Publication Date
NL970044I1 true NL970044I1 (nl) 1998-03-02
NL970044I2 NL970044I2 (nl) 1998-06-02

Family

ID=27526589

Family Applications (1)

Application Number Title Priority Date Filing Date
NL970044C NL970044I2 (nl) 1990-04-27 1997-12-19 Benzimidazoolderivaten, de bereiding en toepassingdaarvan.

Country Status (22)

Country Link
US (4) US5196444A (nl)
EP (2) EP0720982B1 (nl)
JP (2) JP2514282B2 (nl)
KR (1) KR100200541B1 (nl)
CN (2) CN1048486C (nl)
AT (2) ATE146779T1 (nl)
CA (2) CA2040955C (nl)
CY (1) CY2150B1 (nl)
DE (3) DE69133149T2 (nl)
DK (2) DK0720982T3 (nl)
ES (2) ES2181742T3 (nl)
FI (2) FI108434B (nl)
GR (1) GR3022172T3 (nl)
HK (1) HK1000803A1 (nl)
HU (2) HU213266B (nl)
IE (1) IE911317A1 (nl)
LU (1) LU90224I2 (nl)
LV (1) LV10258B (nl)
NL (1) NL970044I2 (nl)
NO (3) NO300923B1 (nl)
NZ (1) NZ237949A (nl)
PT (1) PT97451B (nl)

Families Citing this family (226)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223499A (en) * 1989-05-30 1993-06-29 Merck & Co., Inc. 6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
US5332744A (en) * 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
DE4036706A1 (de) * 1990-11-17 1992-05-21 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
GB9027208D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027198D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
FR2673427B1 (fr) * 1991-03-01 1993-06-18 Sanofi Elf Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
TW274551B (nl) * 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
US5354759A (en) * 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
GB9201789D0 (en) * 1992-01-28 1992-03-11 Fujisawa Pharmaceutical Co Heterocyclic derivatives
TW284688B (nl) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
JP2682353B2 (ja) * 1991-11-20 1997-11-26 武田薬品工業株式会社 経口用医薬組成物およびその製造法
DE4203872A1 (de) * 1992-02-11 1993-08-12 Thomae Gmbh Dr K Imidazo(1,2-a)pyridine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1993018030A1 (en) * 1992-03-03 1993-09-16 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives as angiotensin ii antagonists
US5310929A (en) * 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
US5266583A (en) * 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
DK154092D0 (da) * 1992-12-23 1992-12-23 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
CA2115985A1 (en) * 1993-02-25 1994-08-26 Kohei Nishikawa Vascular hypertrophy suppressor
JP2787539B2 (ja) * 1993-02-26 1998-08-20 松森　　昭 ウイルス性疾患の予防または治療剤
JP2003306432A (ja) * 1993-04-22 2003-10-28 Takeda Chem Ind Ltd 腎疾患の予防または治療剤
JP3810020B2 (ja) * 1993-04-22 2006-08-16 武田薬品工業株式会社 腎疾患の予防または治療剤
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
US5721263A (en) 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
US5391566A (en) * 1993-07-20 1995-02-21 Merck & Co., Inc. Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
ZA945190B (en) * 1993-07-30 1995-02-24 Kotobuki Seiyaku Co Ltd Carboxymethylidenecycloheptimidazole derivatives method or manufacturing the same and therapeutic agents containing these compounds
US5824696A (en) * 1993-09-01 1998-10-20 Smithkline Beecham Corporation Medicaments
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
DK0668272T3 (da) * 1994-01-28 2000-09-18 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af tetrazolylforbindelser
DE4408497A1 (de) * 1994-03-14 1995-09-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1110551B1 (en) * 1994-03-16 2004-05-12 Sankyo Company Limited Ocular tension lowering agent
AU677702B2 (en) * 1994-10-13 1997-05-01 Takeda Pharmaceutical Company Limited A prophylactic or therapeutic drug for renal diseases
SE9501881D0 (sv) * 1995-05-19 1995-05-19 Astra Ab New pharmacological use of AII-receptor antagonists
SE9502219D0 (sv) * 1995-06-19 1995-06-19 Astra Ab Novel medical use
EP0853477B1 (en) * 1995-10-06 2002-10-09 Novartis AG At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
AU722514B2 (en) * 1995-12-28 2000-08-03 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
ATE230263T1 (de) 1996-02-29 2003-01-15 Novartis Erfind Verwalt Gmbh At1 rezeptor antagonist zur anregung von apoptosis
DK0914158T4 (da) * 1996-04-05 2006-03-06 Takeda Pharmaceutical Farmaceutisk kombination indeholdende en forbindelse med angiotensin II antagonistisk aktivitet og en forbindelse, der öger insulin-sensitiviteten
US5771604A (en) * 1997-04-07 1998-06-30 Maytag Corporation Clothes dryer air inlet arrangement
US6177587B1 (en) 1997-05-26 2001-01-23 Takeda Chemical Industries, Ltd. Production method of aminobenzene compound
TW453999B (en) 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
KR20010031177A (ko) 1997-10-17 2001-04-16 유로진 리미티드 레닌-안지오텐신 시스템 억제제의 용도
AU745838B2 (en) * 1998-02-23 2002-04-11 Kureha Chemical Industry Co., Ltd. Benzimidazole derivative
DE19820151A1 (de) * 1998-05-06 1999-11-11 Hexal Ag Transdermales therapeutisches System zur Anwendung von Candesartan
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
BR9912098A (pt) 1998-07-15 2001-09-25 Teijin Ltd Derivado de tiobenzimidazol, composição farmacêutica, e, agente preventivo e/ou terapêutico
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
NZ553010A (en) 1998-12-23 2008-09-26 Novartis Ag Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
ATE487491T1 (de) 1999-02-19 2010-11-15 Takeda Pharmaceutical Präparationen zur perkutanen aufnahme von zusammnesetzungen die einen angiotensin-ii- rezeptorantagonismus aufweisen
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
IL146971A0 (en) * 1999-06-10 2002-08-14 Warner Lambert Co Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
US6972287B1 (en) 1999-06-10 2005-12-06 Pfizer Inc. Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
US6852743B1 (en) * 1999-07-21 2005-02-08 Takeda Pharmaceutical Company Limited Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
JP4870888B2 (ja) * 1999-08-30 2012-02-08 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 心血管の病態の予防におけるレニン−アンギオテンシン系阻害剤の使用
HUP0301057A3 (en) * 2000-02-18 2004-01-28 Takeda Pharmaceutical Angiotenzin ii antagonist heterocyclic compound an their use for preparation of tnf-alpha inhibitors
SE0002353D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New use
ATE385498T1 (de) * 2000-08-11 2008-02-15 Boehringer Ingelheim Pharma Heterozyklische verbindungen als inhibitoren von tyrosin-kinasen
AR033390A1 (es) 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
WO2002017913A1 (fr) * 2000-08-30 2002-03-07 Sankyo Company, Limited Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque
AU2002210925A1 (en) * 2000-10-25 2002-05-06 Takeda Chemical Industries Ltd. Preventives/remedies for portal hypertension
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
DE60136958D1 (de) 2000-12-01 2009-01-22 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
US7067546B2 (en) * 2001-08-03 2006-06-27 Takeda Pharmaceutical Company Crystal and process for producing the same
CN1589154A (zh) * 2001-08-28 2005-03-02 三共株式会社 含有血管紧张肽ii受体拮抗剂的药用组合物
US7107198B2 (en) * 2001-11-02 2006-09-12 Sun Microsystems, Inc. Automatic generation of reduced-size circuit models including inductive interaction
US7812044B2 (en) 2001-11-13 2010-10-12 Takeda Pharmaceutical Company Limited Anticancer agents
DE10205335A1 (de) * 2002-02-07 2003-08-21 Bdd Group Holding Ag Zug Deuterierte biphenylsubstituierte Benzimidazole sowie diese Verbindungen enthaltende Arzneimittel
EP1482896A4 (en) * 2002-03-01 2005-11-23 Merck & Co Inc AMINOALKYLPHOSPHONATES AND ASSOCIATED COMPOUNDS AS EDG RECEPTOR AGONISTS
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
RS20050106A (en) 2002-08-19 2007-11-15 Pfizer Products Inc., Combination therapy for hyperproliferative diseases
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
ES2238022T3 (es) * 2003-03-17 2008-11-01 Teva Pharmaceutical Industries Ltd. Poliformos de valsartan.
US7504516B2 (en) * 2003-03-27 2009-03-17 Hetero Drugs Limited Crystalline forms of candesartan cilexetil
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
WO2004094391A2 (en) * 2003-04-21 2004-11-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valsartan and intermediates thereof
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
PT1658281E (pt) * 2003-08-27 2010-10-12 K S Zentiva Método de remoção do grupo protector trifenilmetano
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
TW200523257A (en) * 2003-09-26 2005-07-16 Novartis Ag Use of organic compounds
US7098342B2 (en) * 2003-10-16 2006-08-29 Teva Pharmaceutical Industries Ltd. Preparation of candesartan cilexetil
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
RU2422450C2 (ru) 2003-11-19 2011-06-27 Метабазис Терапеутикс, Инк. Новые фосфорсодержащие тиромиметики
WO2005051928A1 (en) * 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited Process for production of tetrazolyl compounds
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
JP2005206603A (ja) * 2004-01-21 2005-08-04 Teva Pharmaceutical Industries Ltd カンデサルタンシレキセチルの調製
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
EP1713795A2 (en) * 2004-02-11 2006-10-25 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
JP2007529459A (ja) 2004-03-17 2007-10-25 ノバルティス アクチエンゲゼルシャフト 治療に置けるレニン阻害剤の使用
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
EP1742938A1 (en) * 2004-05-05 2007-01-17 Teva Pharmaceutical Industries Ltd. Preparation of candesartan cilexetil in high purity
JP2009185060A (ja) * 2004-05-19 2009-08-20 Teva Pharmaceutical Industries Ltd カンデサルタンシレキセチル多形体
JP2005330277A (ja) * 2004-05-19 2005-12-02 Teva Pharmaceutical Industries Ltd カンデサルタンシレキセチル多形体
WO2005117591A2 (en) * 2004-05-28 2005-12-15 Andrx Labs Llc Novel pharmaceutical formulation containing a biguanide and an angiotensin antagonist
WO2005123720A1 (en) * 2004-06-18 2005-12-29 Ranbaxy Laboratories Limited Fine particles of the angiotensin ii antagonist candesartan cilexetil and process for production thereof
BRPI0514549A (pt) 2004-08-23 2008-06-17 Wyeth Corp ácidos de pirrol-naftila como inibidores de pai-1
KR20070045353A (ko) 2004-08-23 2007-05-02 와이어쓰 플라스미노겐 활성화제 억제제-1의 억제제로서티아졸로-나프틸 산
CA2577857A1 (en) 2004-08-23 2006-03-02 Wyeth Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
US20080085914A1 (en) 2004-10-08 2008-04-10 David Louis Feldman Use Of Organic Compounds
RU2007115900A (ru) 2004-10-27 2008-11-10 Дайити Санкио Компани, Лимитед (Jp) Производные бензола, имеющие 2 или более заместителей
EP1806137A4 (en) * 2004-10-29 2011-03-30 Kowa Co THERAPEUTIC AGENT FOR THE TREATMENT OF GLOMERULAR DISEASE
EP1655298A1 (en) * 2004-11-03 2006-05-10 LEK Pharmaceuticals d.d. Novel polymorph forms of candesartan cilexetil
EP1812423A1 (en) 2004-11-11 2007-08-01 LEK Pharmaceuticals D.D. Process for the synthesis of tetrazoles
CA2590533C (en) * 2004-11-23 2010-09-07 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
DE102004060699A1 (de) * 2004-12-16 2006-06-22 Ratiopharm Gmbh Verfahren zur Herstellung von Candesartan
PT1833801E (pt) * 2004-12-22 2008-08-25 Algry Quimica S L Compostos intermediários para a preparação de antagonistas do receptor da angiotensina ii
US20060165806A1 (en) * 2005-01-06 2006-07-27 Elan Pharma International Limited Nanoparticulate candesartan formulations
EP1836195A2 (en) * 2005-01-14 2007-09-26 Teva Pharmaceutical Industries Ltd Preparation of crude candesartan cilexetil
ES2371145T3 (es) * 2005-01-26 2011-12-27 Lek Pharmaceuticals D.D. Nueva composición farmacéutica que contiene candesartán cilexetilo como sustancia cristalina lipófila.
AU2006231418B2 (en) * 2005-03-30 2011-10-13 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use as angiotensin II antagonist
TW200719896A (en) * 2005-04-18 2007-06-01 Astrazeneca Ab Combination product
CN100400536C (zh) * 2005-04-30 2008-07-09 重庆圣华曦药业有限公司 坎地沙坦酯c-型晶体的制备方法
KR100978592B1 (ko) * 2005-05-10 2010-08-27 테바 파마슈티컬 인더스트리즈 리미티드 안정한 미세 분말 칸데사탄 실렉세틸 및 이것의 제조 방법
EP1896455A2 (en) 2005-06-06 2008-03-12 Medichem, S.A. Process for the preparation of tetrazolyl compounds
ES2264641B1 (es) * 2005-06-17 2008-03-01 Quimica Sintetica, S.A. Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios.
CN101263136A (zh) 2005-07-13 2008-09-10 弗·哈夫曼-拉罗切有限公司 作为5-ht6、5-ht24的苯并咪唑衍生物
SI22127A (sl) 2005-10-07 2007-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek za pripravo kandesartan cileksetila
CZ299265B6 (cs) * 2005-10-20 2008-05-28 Zentiva, A. S. Zpusob výroby 1-(cyklohexyloxykarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)bifenyl-4-yl]methyl]benzimidazol-7-karboxylátu (candesartan cilexetilu)
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CN100344625C (zh) * 2005-12-22 2007-10-24 浙江天宇药业有限公司 一种制备坎地沙坦的方法
WO2007094015A1 (en) * 2006-02-15 2007-08-23 Matrix Laboratories Ltd An improved process for the preparation of candesartan cilexetil
CN101024643A (zh) 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
WO2008035360A2 (en) * 2006-06-13 2008-03-27 Alembic Limited Novel crystalline forms of candesartan cilexetil, candesartan, tritylated candesartan and tritylated candesartan cilexetil
EP2049510A1 (en) * 2006-07-28 2009-04-22 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of candesartan cilexetil form i
AU2007282400B2 (en) 2006-08-10 2012-08-30 Takeda Pharmaceutical Company Limited Pharmaceutical composition
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
US8143435B2 (en) * 2006-10-10 2012-03-27 Mylan Laboratories Ltd. One pot process for the preparation of candesartan
EP2486910A3 (en) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Multi-chambered apparatus comprising a dispenser head
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
CA2671816C (en) * 2006-12-06 2012-06-05 Shanghai Allist Pharmaceutical., Inc. Salts of imidazole-5-carboxylic acid derivatives, a method for preparing same and pharmaceutical compositions comprising same
CN101214242A (zh) 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
EP1952806A1 (en) 2007-02-01 2008-08-06 Helm AG Process for the preparation of adsorbates of candesartan
TW200838501A (en) * 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
CA2677661A1 (en) 2007-02-07 2008-08-14 Kyowa Hakko Kirin Co., Ltd. Tricyclic compounds
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
ES2351542T3 (es) * 2007-03-08 2011-02-07 Teva Pharmaceutical Industries Ltd. Composición farmacéutica que comprende candesartan cilexetilo.
JP5283632B2 (ja) * 2007-03-28 2013-09-04 武田薬品工業株式会社 ベンズイミダゾール−７−カルボキシレート誘導体およびｐＨ調整剤を含有する固形医薬組成物
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
SI22488A (sl) * 2007-04-24 2008-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalni 1-(cikloheksiloksikarboniloksi)etil 1-((2'-cianobifenil-4-il)metil) - 2-etoksi-1h-benz(d)imidazol -7-karboksilat in proces za njegovo pripravo
RU2009141539A (ru) 2007-04-25 2011-05-27 Тева Фармасьютикал Индастриес Лтд. (Il) Комплекс фармацевтического наполнителя
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
WO2009007986A1 (en) * 2007-07-11 2009-01-15 Alembic Limited An improved process for the preparation of candesartan cilexetil
JP2010538071A (ja) 2007-09-07 2010-12-09 セラヴァンス， インコーポレーテッド 二重作用性降圧剤
WO2009076288A1 (en) * 2007-12-11 2009-06-18 Theravance, Inc. Dual-acting benzoimidazole derivative and their use as antihypertensive agents
US8247440B2 (en) 2008-02-20 2012-08-21 Curators Of The University Of Missouri Composition comprising omeprazole, lansoprazole and at least one buffering agent
US7989484B2 (en) 2008-04-29 2011-08-02 Theravance, Inc. Dual-acting antihypertensive agents
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
WO2009157001A2 (en) * 2008-06-24 2009-12-30 Hetero Research Foundation Process for preparation of candesartan cilexetil
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010011821A2 (en) * 2008-07-24 2010-01-28 Theravance, Inc. Dual-acting antihypertensive agents
CN101648918B (zh) * 2008-08-15 2013-01-09 联化科技股份有限公司 坎地沙坦酯的中间体化合物及其合成方法
SI2165702T1 (sl) 2008-09-17 2012-05-31 Helm Ag Stabilni in z lahkoto raztopljeni sestavki kandesartan cileksetila pripravljeni z vlažno granulacijo
AU2009302285A1 (en) * 2008-10-10 2010-04-15 Janssen Pharmaceutica Nv Combination therapy comprising angiotensin receptor blockers and vasopressin receptor antagonists
KR100995755B1 (ko) 2008-10-31 2010-11-19 일동제약주식회사 트리틸 칸데사르탄 실렉세틸의 개선된 제조방법
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
WO2011005674A1 (en) 2009-07-07 2011-01-13 Theravance, Inc. Dual-acting pyrazole antihypertensive agents
EP2456762B1 (en) 2009-07-22 2013-10-16 Theravance, Inc. Dual-acting oxazole antihypertensive agents
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
WO2011080684A1 (en) 2009-12-31 2011-07-07 Ranbaxy Laboratories Limited Process for the preparation of candesartan cilexetil
EP2526095A1 (en) 2010-01-19 2012-11-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
WO2011092666A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited An improved process for the preparation of candesartan cilexetil, polymorphic forms of n-trityl candesartan and their uses thereof
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
CN102791704B (zh) 2010-03-10 2015-11-25 前体生物药物股份公司 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
CN101880241B (zh) * 2010-07-14 2013-04-17 浙江美诺华药物化学有限公司 一锅法制备2-(取代苯基)甲氨基-3-硝基苯甲酸甲酯的方法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR101251741B1 (ko) * 2010-12-16 2013-04-05 동화약품주식회사 칸데사르탄실렉세틸의 개선된 제조방법
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
CN102198129B (zh) * 2011-03-22 2016-03-30 浙江华海药业股份有限公司 含有坎地沙坦酯和氢氯噻嗪的口服片剂
CN102206186A (zh) * 2011-04-18 2011-10-05 张家港市信谊化工有限公司 坎地沙坦环合物的制备方法
US9446032B2 (en) 2011-08-26 2016-09-20 Wockhardt Limited Methods for treating cardiovascular disorders
WO2013041944A1 (en) 2011-09-19 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of micronized candesartan cilexetil
JP5850697B2 (ja) * 2011-10-18 2016-02-03 株式会社トクヤマ カンデサルタンシレキセチルの製造方法
WO2013090196A1 (en) 2011-12-15 2013-06-20 Takeda Pharmaceuticals U.S.A., Inc. Combinations of azilsartan and chlorthalidone for treating hypertension black patients
CN102391254B (zh) * 2011-12-16 2013-03-13 珠海润都制药股份有限公司 一种坎地沙坦的制备方法
CN103304543A (zh) * 2012-03-12 2013-09-18 邓俐丽 一种坎地沙坦酯的制备方法
CN102633816A (zh) * 2012-03-30 2012-08-15 李莎 头孢西丁酯化前体药物化合物及口服制剂
CA2911041C (en) 2012-05-01 2020-12-15 Shelley Romayne BOYD Methods for treating and diagnosing blinding eye diseases
CN104507459A (zh) 2012-05-07 2015-04-08 拜耳制药股份公司 包含硝苯地平和坎地沙坦酯的药物剂型的制造方法
US20140134187A1 (en) 2012-06-25 2014-05-15 The Johns Hopkins University Therapeutic and diagnostic methods for autism spectrum disorders and other conditions
US9486503B2 (en) 2012-10-04 2016-11-08 Shionogi & Co., Ltd. Medicinal agent for suppressing malignant tumor metastasis
CN102952040A (zh) * 2012-11-20 2013-03-06 峨眉山天梁星制药有限公司 一种坎地沙坦酯中间体的硝基还原为氨基的方法
PL236001B1 (pl) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9339542B2 (en) * 2013-04-16 2016-05-17 John L Couvaras Hypertension reducing composition
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
ES2847904T3 (es) 2013-07-23 2021-08-04 Daiichi Sankyo Co Ltd Medicamento para la prevención o el tratamiento de la hipertensión
CN104098550A (zh) * 2014-07-17 2014-10-15 浙江华海药业股份有限公司 一种精制三苯甲基坎地沙坦的方法
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
EP3312174B1 (en) * 2015-06-05 2019-12-18 Zhejiang Huahai Pharmaceutical Co., Ltd Method for preparing trityl candesartan
CZ2015687A3 (cs) 2015-10-02 2017-04-12 Zentiva, K.S. Farmaceutická kompozice obsahující kombinaci kandesartanu, amlodipinu a hydrochlorthiazidu
EP3219309A1 (en) 2016-03-17 2017-09-20 K.H.S. Pharma Holding GmbH Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
JP6934859B2 (ja) 2016-03-24 2021-09-15 第一三共株式会社 腎疾患の治療のための医薬
CN106432201B (zh) * 2016-09-14 2019-04-23 威海迪素制药有限公司 一种坎地沙坦酯结晶的制备方法
CA3067918A1 (en) 2017-07-07 2019-01-10 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonish for the prevention or treatment of hypertension in cats
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
JP2021521173A (ja) 2018-04-11 2021-08-26 オハイオ・ステイト・イノベーション・ファウンデーション 眼内薬物送達用の持続放出微粒子のための方法及び組成物
CN113544113B (zh) 2019-01-02 2023-12-26 临海市华南化工有限公司 一种坎地沙坦酯中间体的合成方法
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
CN110514758A (zh) * 2019-08-21 2019-11-29 天地恒一制药股份有限公司 一种坎地沙坦酯有关物质的检测方法
CN114728883A (zh) * 2020-08-13 2022-07-08 南京海融医药科技股份有限公司 布洛芬酯类前药、药物组合物以及制备方法和应用
US11655220B2 (en) 2020-10-22 2023-05-23 Hetero Labs Limited Process for the preparation of angiotensin II receptor blockers
EP4052695A1 (en) 2021-03-05 2022-09-07 Midas Pharma GmbH Stable oral fixed-dose immediate release pharmaceutical compositions comprising amlodipine, atorvastatin and candesartan cilexetil
WO2023285646A1 (en) 2021-07-15 2023-01-19 Adamed Pharma S.A A pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
CN114149414B (zh) * 2021-12-23 2023-08-04 浙江永宁药业股份有限公司 一种利用微反应器连续流制备坎地沙坦的方法
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526896A (en) * 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
JPS5671073A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4775679A (en) * 1985-04-25 1988-10-04 Merck & Co., Inc. Certain heterocyclic-ethyl-2,3-dihydrobenzofurans useful as anti-inflammatory agents
US4812462A (en) * 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4820843A (en) * 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4764623A (en) * 1987-06-15 1988-08-16 American Home Products Corporation N-(1H-tetrazol-5-yl-alkylphenyl)polyfluoroalkanamides
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
DE3928177A1 (de) * 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0400835A1 (en) * 1989-05-15 1990-12-05 Merck & Co. Inc. Substituted benzimidazoles as angiotensin II antagonists
GB8911854D0 (en) * 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
US5250554A (en) * 1989-10-24 1993-10-05 Takeda Chemical Industries, Ltd. Benzimidazole derivatives useful as angiotensin II inhibitors
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof

Also Published As

Publication number Publication date
FI108434B (fi) 2002-01-31
ATE227709T1 (de) 2002-11-15
DE19875004I2 (de) 2002-03-28
DE69123784T2 (de) 1997-04-17
CN1147515A (zh) 1997-04-16
EP0720982A1 (en) 1996-07-10
ES2095266T3 (es) 1997-02-16
DK0459136T3 (da) 1997-04-01
AU7533191A (en) 1991-11-21
NO911586L (no) 1991-10-28
CA2040955C (en) 1998-02-03
ATE146779T1 (de) 1997-01-15
KR100200541B1 (ko) 1999-06-15
CA2040955A1 (en) 1991-10-28
FI911936A0 (fi) 1991-04-22
EP0459136B1 (en) 1996-12-27
FI982761A (fi) 1998-12-21
CN1048486C (zh) 2000-01-19
AU647469B2 (en) 1994-03-24
JP2853611B2 (ja) 1999-02-03
LV10258A (lv) 1994-10-20
HU911347D0 (en) 1991-10-28
DK0720982T3 (da) 2003-03-17
NO970195L (no) 1997-01-16
NO302752B1 (no) 1998-04-20
NO970195D0 (no) 1997-01-16
ES2181742T3 (es) 2003-03-01
US5401764A (en) 1995-03-28
GR3022172T3 (en) 1997-03-31
HU213266B (en) 1997-04-28
FI982761A0 (fi) 1998-12-21
US5196444A (en) 1993-03-23
CN1058966C (zh) 2000-11-29
NO911586D0 (no) 1991-04-22
DE69123784D1 (de) 1997-02-06
CA2204290C (en) 2001-12-18
LU90224I2 (fr) 1998-05-11
EP0720982B1 (en) 2002-11-13
IE911317A1 (en) 1991-11-06
KR910018359A (ko) 1991-11-30
PT97451B (pt) 1997-01-31
FI114983B (fi) 2005-02-15
PT97451A (pt) 1992-01-31
DE69133149D1 (de) 2002-12-19
HK1000803A1 (en) 1998-05-01
HU210871A9 (en) 1995-08-28
HUT57736A (en) 1991-12-30
NZ237949A (en) 1995-07-26
CN1055927A (zh) 1991-11-06
NO1998018I1 (no) 1998-06-25
US5328919A (en) 1994-07-12
CY2150B1 (en) 2002-08-23
US5705517A (en) 1998-01-06
FI911936A (fi) 1991-10-28
CA2204290A1 (en) 1991-10-28
JPH0899960A (ja) 1996-04-16
DE69133149T2 (de) 2003-03-13
NL970044I2 (nl) 1998-06-02
JP2514282B2 (ja) 1996-07-10
JPH04364171A (ja) 1992-12-16
LV10258B (en) 1995-04-20
NO300923B1 (no) 1997-08-18
EP0459136A1 (en) 1991-12-04

Similar Documents

Publication Publication Date Title
NL970044I2 (nl) Benzimidazoolderivaten, de bereiding en toepassingdaarvan.
TR199701218T2 (xx) Benzimidazol bile�ikleri ve bunlar� i�eren farmakolojik bile�imler.
KR920006335A (ko) 안지오텐신 ⅱ수용체 길항제
DE69329727T2 (de) Neue imidazol derivate, ihre herstellung und therapeutische verwendung
KR930701415A (ko) 약학적으로 활성인 벤조퀴나졸린 화합물
TR199900719A2 (xx) Fenoksi asetik asit ve fenoksimetil tetrazol t�revleri.
DE69002384T2 (de) Heterocyclische Guanidine als 5HT-3-Antagonisten.
NZ309499A (en) Styryl benzimidazole derivatives useful as inhibitors of smooth muscle cell proliferation
ATE31925T1 (de) 2-(formylamino)-n-(1h-tetrazol-5-yl)benzamide.
IT1209127B (it) Derivati eterociclici azotati adattivita'terapeutica ,processi per la loro preparazione e composizioni farmaceutiche contenenti detti derivati
TR199701185A2 (xx) Sefalosporin piridinyum t�revleri.